ModifiedCignaPolicy N/A

Weight Loss - Glucagon-Like Peptide-1 Agonists Prior Authorization Policy

Defines Cigna's prior authorization coverage policy for liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound) for weight management and related indications, affecting providers submitting authorization requests under Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyWeight Loss - Glucagon-Like Peptide-1 Agonists Prior Authorization Policy

Policy CodePolicy N/A

Change TypeMaterial updates: added products and revised continuation/indication criteria

Effective DateJul 9, 2025

Next Review DateJul 9, 2025

Key ActionSubmit prior authorization requests with plan-consistent documentation including applicable diagnosis/procedure codes and required specialist documentation for MASH when prescribing Wegovy.

SourceLink

POLICY UPDATE CHANGES

Zepbound was added to the policy and new criteria were created for it.

Baseline BMI/weight criteria were modified to clarify 'baseline' refers to measurements prior to any GLP-1 or GLP-1/GIP agonist (e.g., Saxenda, Wegovy, Zepbound) rather than prior to initiation of a specific product.

Dosing-related continuation requirements (tolerating maintenance dose or titration windows) were removed and approval duration for continuing therapy standardized to 1 year for Wegovy and Zepbound (and adjusted for Saxenda).

Wegovy indication expanded to include major adverse cardiovascular event (MACE) risk reduction in patients with established cardiovascular disease who are overweight or obese, with clarification re: prior stroke excluding TIA.

Obstructive sleep apnea (moderate to severe) in a patient with obesity was added as an FDA-approved indication for Zepbound.

Concomitant use with other GLP-1 or GLP-1/GIP agonists or other FDA-approved weight-loss medications is not recommended/clarified in conditions not covered.

Wegovy added for metabolic dysfunction-associated steatohepatitis (MASH)/NASH as a condition of approval with documentation and specialist-prescribing requirement.

Liraglutide (generic to Saxenda) was added to the policy and targeted for prior authorization alongside Saxenda, Wegovy, and Zepbound.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

3medications covered (Saxenda, Wegovy, Zepbound)

2.4 mg QWWegovy maintenance dose

15 mg QWZepbound max dose

≥12 yrspediatric age threshold

1 yrstandardized approval duration (Wegovy, Zepbound)

MASH/NASHnew MASH indication requirement

Coverage Criteria

Coverage criteria (label- and guideline-informed)

Covered when consistent with FDA indications, labeling, and clinical guideline context as follows:

Adult label indications: Patient meets the FDA-labeled indication for the specific agent (e.g., adults with overweight plus ≥1 weight‑related comorbidity, or adults with obesity). Wegovy includes additional FDA indications for MACE risk reduction in adults with established cardiovascular disease and for treatment of non‑cirrhotic MASH with F2–F3 fibrosis; Zepbound includes treatment of moderate to severe obstructive sleep apnea in adults with obesity.see agent-specific labeling

Source: FDA indications and overview

Pediatric label indications: For liraglutide (Saxenda, generic) and Wegovy, patient meets pediatric labeling (≥ 12 years) and any label-specified weight/BMI thresholds (e.g., liraglutide pediatric: ≥ 12 years and ≥ 60 kg).>=12 years

Source: prescribing information and pediatric guidelines

Adjunct to lifestyle modification: Therapy is used in combination with a reduced‑calorie diet and increased physical activity; pharmacotherapy is generally an adjunct to intensive lifestyle intervention and may be considered after inadequate response to such interventions per guideline context.document prior lifestyle interventions when applicable

Source: overview and guideline summaries

Dose escalation and maintenance considerations: Providers should follow the agent-specific dose‑escalation schedules and evaluate response at label-specified timepoints (examples: Wegovy escalation over 16 weeks to reach 2.4 mg QW maintenance; liraglutide evaluate adult body weight at 16 weeks and discontinue if <4% weight loss from baseline; pediatric liraglutide evaluate BMI after 12 weeks on maintenance and discontinue if <1% BMI reduction). Zepbound titration starts 2.5 mg QW and increases every ≥4 weeks to maintenance options 5/10/15 mg QW (max 15 mg QW).see prescribing information (timepoints and dose targets)

Sources: dosing sections for Wegovy, liraglutide, Zepbound

Baseline definition: Baseline measurements referenced in continuation/non‑response rules refer to measurements taken prior to any GLP‑1 or GLP‑1/GIP agonist (e.g., prior to any use of Saxenda, Wegovy, or Zepbound).baseline = prior to any GLP-1 or GLP-1/GIP agonist

Source: history and baseline clarification

Continuation and approval duration: Continuation determinations follow documented clinical response and labeling; dosing‑tolerance requirements previously tied to continuation were removed and approval durations standardized (e.g., continuing therapy approvals changed to 1 year for Wegovy and Zepbound; Saxenda continuation criteria adjusted per policy history).annual reauthorization as specified

Source: policy history on continuation criteria and approval durations

Concomitant use exclusion: None of the GLP‑1 or GLP‑1/GIP agonists are recommended for coadministration with other GLP‑1 or GLP‑1/GIP agonists; concomitant use with other FDA‑approved weight‑loss medications is not recommended and may be considered not medically necessary.

Source: dosing section and conditions not covered

Covered indications (high level)

Coverage is conditional — products are covered for FDA‑approved weight‑loss indications when documented criteria are met; several indications and criteria were added or revised.

Products covered when FDA‑approved indication met: Liraglutide (Saxenda, generic), Wegovy (semaglutide), and Zepbound (tirzepatide) are covered with prior authorization for their FDA‑approved weight‑loss indications, including adult and pediatric obesity as labeled.FDA‑approved indication

Policy targets these products

Wegovy — additional covered indications: Wegovy is covered for reduction of MACE risk in adults with established cardiovascular disease who are overweight or obese (note: prior stroke does not include TIA) and for non‑cirrhotic MASH (F2–F3 fibrosis) with documentation and specialist prescribing or consultation required.FDA‑approved indication; documentation for MASH/NASH; specialist prescriber required

See Wegovy indications and policy history

Zepbound — additional covered indication:

None of the GLP-1 or GLP-1/GIP agonists are recommended for coadministration with other GLP-1 or GLP-1/GIP agonists. This policy follows the product prescribing information which explicitly states that coadministration of these agents is not recommended.

Concomitant use of the targeted products with other GLP‑1 agonists or GLP‑1/GIP receptor agonists, and concomitant use with other medications that are FDA‑approved for weight loss, is noted as not recommended for approval. Such concomitant regimens may be considered outside the scope of this coverage policy and could be subject to denial.

Services or medications billed for conditions or diagnoses that are not covered under this coverage policy will be denied as not covered per the member's benefit plan terms. Providers must submit requests using the most appropriate diagnosis and procedure codes; claims lacking covered codes for the service will be denied.

Concomitant use is a specific condition addressed by this policy: combining a GLP‑1 or GLP‑1/GIP agonist with another agent in the same class or with other FDA‑approved weight‑loss medications is not recommended and may be treated as not medically necessary. The prescribing information and the policy history note this exclusion to prevent coadministration of multiple incretin-based agents or simultaneous use with other approved anti‑obesity drugs.

Coding and Dosing Timelines

Targeted products (NDC)NDC

NDC	liraglutide (Saxenda, generic), Wegovy (semaglutide), Zepbound (tirzepatide) — policy targets these products

inv-08: Liraglutide adult weight-loss evaluation timepoint

Adult evaluation timepointEvaluate body weight at 16 weeks after initiating liraglutide; discontinue if patient has not lost ≥ 4% of baseline body weight.

Adult maintenance dose toleranceRecommended maintenance dose is 3 mg SC once daily; discontinue if the patient cannot tolerate 3 mg.

Dose-escalation guidancePrescribing information outlines a 4-week dose escalation schedule; if a patient does not tolerate an increased dose, consider delaying escalation ~1 additional week.

inv-09: Liraglutide pediatric BMI evaluation timepoint

Pediatric BMI evaluation timepointEvaluate BMI after 12 weeks on the liraglutide maintenance dose; discontinue if BMI has not reduced by ≥ 1% from baseline.

Pediatric maintenance dose

Provider Actions and Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization Required — For benefits administered by Cigna, prior authorization is required for Saxenda, Wegovy, and Zepbound. Submit requests consistent with the member's benefit plan; prior authorization determinations depend on the applicable plan terms.

Applies to Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide).
Prior authorization is recommended for prescription benefit coverage of liraglutide (Saxenda generic), Wegovy, and Zepbound.

Documentation Required

Submit Plan-Consistent Documentation

Submit documentation consistent with the member's benefit plan. Provide sufficient supporting information to demonstrate the requested service meets the applicable coverage criteria.

Include clinical documentation such as chart notes, lab results, medical test results, claims records, prescription receipts, and other relevant records as applicable.

Background

Liraglutide (Saxenda, generic), semaglutide (Wegovy), and tirzepatide (Zepbound) are glucagon‑like peptide‑1 receptor agonists (tirzepatide is a dual GLP‑1/GIP receptor agonist) indicated for weight management in conjunction with reduced‑calorie diet and increased physical activity. Wegovy has additional FDA‑approved indications including reduction of major adverse cardiovascular events in adults with established cardiovascular disease and treatment of metabolic dysfunction‑associated steatohepatitis (MASH) in specified patients; Zepbound also has indications that include treatment of obstructive sleep apnea in adults with obesity. Providers should follow the agents' labeled dose‑escalation schedules and evaluation timepoints when initiating and monitoring therapy.

Definitions

inv-21: MACE definition

MACE definition (SELECT context)Major adverse cardiovascular events (MACE) defined as cardiovascular death, non‑fatal myocardial infarction, or non‑fatal stroke.

Wegovy indication linkWegovy is indicated to reduce the risk of MACE in adults with established cardiovascular disease and overweight or obesity.

Trial contextMACE definition is used in the SELECT trial context for CV risk reduction labeling of Wegovy.

inv-22: MASH definition

MASH definitionMetabolic dysfunction‑associated steatohepatitis (MASH; formerly NASH) with moderate to advanced liver fibrosis consistent with stages F2–F3 fibrosis.

ESSENCE trial enrollmentESSENCE trial enrolled adults ≥18 years with histological steatohepatitis and stage F2–F3 fibrosis per NASH CRN classification (NAS ≥4 with ≥1 in each component).

Policy Summary

PayerCigna

PolicyWeight Loss - Glucagon-Like Peptide-1 Agonists Prior Authorization Policy

Policy CodePolicy N/A

Change TypeMaterial updates: added products and revised continuation/indication criteria

Effective DateJul 9, 2025

Next Review DateJul 9, 2025

Key ActionSubmit prior authorization requests with plan-consistent documentation including applicable diagnosis/procedure codes and required specialist documentation for MASH when prescribing Wegovy.

SourceLink

On This Page

Zepbound is covered for weight loss in adults with overweight or obesity and for treatment of moderate to severe obstructive sleep apnea in adults with obesity (sleep study still required).

FDA‑approved indication

See Zepbound indications and policy history

Prior authorization requirement: Prior authorization is required (or recommended per benefit administration) for Saxenda (liraglutide), Wegovy, and Zepbound; coverage determinations depend on the member's specific benefit plan and clinical review.

Source: policy statement and prior authorization notes

Baseline measurement note: Baseline BMI/weight criteria were clarified across agents: 'baseline' refers to measurements prior to any GLP‑1 or GLP‑1/GIP agonist (e.g., prior to any use of Saxenda, Wegovy, or Zepbound).

Source: history sections

Recommended maintenance dose is 3 mg SC once daily; if not tolerated, maintenance dose may be reduced to 2.4 mg QD and discontinue if 2.4 mg is not tolerated.

Pediatric titration windowIf a pediatric patient does not tolerate an increased dose during titration, the dose may be lowered to the prior dose level; dose escalation may take up to 8 weeks.

inv-10: Wegovy dose escalation timeline

Wegovy escalation timelineDose is escalated over 16 weeks to reach the 2.4 mg SC once‑weekly maintenance dose (2.4 mg reached at start of Week 17).

Maintenance dose optionsMaintenance dose for CV risk reduction and weight reduction is 2.4 mg (recommended) or 1.7 mg SC QW; consider response and tolerability when selecting dose.

Tolerability adjustmentsIf a patient does not tolerate a dose during escalation, consider delaying escalation for 4 weeks; for MASH, if 2.4 mg not tolerated, decrease to 1.7 mg and consider re‑escalation.

inv-11: Zepbound dose escalation and max

Starting doseInitiate Zepbound at 2.5 mg SC once weekly (treatment initiation dose, not intended for chronic management).

Escalation increment and intervalAfter 4 weeks, increase to 5 mg QW; thereafter increase in 2.5 mg increments with at least 4 weeks on the current dose before further escalation.

Maintenance and maximum dosesRecommended maintenance doses for weight reduction are 5 mg, 10 mg, or 15 mg QW (OSA maintenance 10 mg or 15 mg QW); maximum dose is 15 mg QW.

Ensure all documentation includes patient-specific identifying information and aligns with the conditions of approval in the member's plan.

Denial Risk

Coding/Coverage Mismatch Denial Risk

Coding/coverage mismatch will result in denial. Claims submitted without covered diagnosis or procedure codes under the applicable coverage policy will be denied as not covered.

Use the most appropriate diagnosis and procedure codes as of the date of service.
Claims for services billed for conditions or diagnoses that are not covered under this policy will be denied.

Step Therapy

Step Therapy and Guideline Context

Step therapy context from clinical guidelines — pharmacotherapy is an adjunct to lifestyle intervention and may be recommended when lifestyle interventions alone are insufficient.

Guidelines (AGA, Endocrine Society, AACE/ACE) recommend adding pharmacologic agents for adults with obesity or overweight with weight-related complications after inadequate response to lifestyle interventions.
Clinical guidance notes effectiveness threshold of ≥5% weight loss at 3 months; if response is insufficient, consider alternative therapies (step therapy implications).
Pharmacotherapy should be used as an adjunct to behavioral modification, not as a standalone treatment.

Billing Rule

Concomitant Use Not Recommended

Concomitant use exclusions — Concomitant use of GLP-1 or GLP-1/GIP receptor agonists with each other or with other FDA‑approved weight‑loss medications is not recommended and is a condition not approved under this policy.

Policy specifies that concomitant use with other GLP‑1 agonists or GLP‑1/GIP agonists is not recommended for approval.
This includes using Saxenda, Wegovy, Zepbound together or with other medications FDA‑approved for weight loss.

Concomitant therapies in trialPatients in ESSENCE could continue stable doses of certain diabetes, lipid‑lowering, and weight‑loss medications; concomitant GLP‑1 or GLP‑1/GIP agonist use was not allowed.

inv-23: Baseline definition

Baseline definitionBaseline refers to measurements taken prior to any GLP‑1 agonist (e.g., Saxenda, Wegovy) or GLP‑1/GIP receptor agonist (e.g., Zepbound).

Policy history changeBaseline BMI/weight criteria were modified across products to clarify baseline refers to measurements before any GLP‑1 or GLP‑1/GIP agonist rather than prior to a specific product initiation.

Application to continuation criteriaNon‑response thresholds (e.g., ≥4% weight loss for adults on liraglutide, ≥1% BMI reduction in pediatrics) reference this baseline definition when evaluating response.